Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy

por Cannarile, Michael A., Weisser, Martin, Jacob, Wolfgang, Jegg, Anna-Maria, Ries, Carola H., Rüttinger, Dominik
Publicado 2017

Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer

por Collins, Denis, Jacob, Wolfgang, Cejalvo, Juan Miguel, Ceppi, Maurizio, James, Ian, Hasmann, Max, Crown, John, Cervantes, Andrés, Weisser, Martin, Bossenmaier, Birgit
Publicado 2017

A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small...

por Cejalvo, Juan-Miguel, Jacob, Wolfgang, Fleitas Kanonnikoff, Tania, Felip, Enriqueta, Navarro Mendivil, Alejandro, Martinez Garcia, Maria, Taus Garcia, Alvaro, Leighl, Natasha, Lassen, Ulrik, Mau-Soerensen, Morten, Adessi, Celine, Michielin, Francesca, James, Ian, Ceppi, Maurizio, Hasmann, Max, Weisser, Martin, Cervantes, Andrés
Publicado 2019

Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients

por Machiels, Jean-Pascal, Gomez-Roca, Carlos, Michot, Jean-Marie, Zamarin, Dmitriy, Mitchell, Tara, Catala, Gaetan, Eberst, Lauriane, Jacob, Wolfgang, Jegg, Anna-Maria, Cannarile, Michael A, Watson, Carl, Babitzki, Galina, Korski, Konstanty, Klaman, Irina, Teixeira, Priscila, Hoves, Sabine, Ries, Carola, Meneses-Lorente, Georgina, Michielin, Francesca, Christen, Randolph, Rüttinger, Dominik, Weisser, Martin, Delord, Jean-Pierre, Cassier, Philippe
Publicado 2020

Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-...

por Schneeweiss, Andreas, Park-Simon, Tjoung-Won, Albanell, Joan, Lassen, Ulrik, Cortés, Javier, Dieras, Veronique, May, Marcus, Schindler, Christoph, Marmé, Frederik, Cejalvo, Juan Miguel, Martinez-Garcia, Maria, Gonzalez, Iria, Lopez-Martin, Jose, Welt, Anja, Levy, Christelle, Joly, Florence, Michielin, Francesca, Jacob, Wolfgang, Adessi, Céline, Moisan, Annie, Meneses-Lorente, Georgina, Racek, Tomas, James, Ian, Ceppi, Maurizio, Hasmann, Max, Weisser, Martin, Cervantes, Andrés
Publicado 2018

Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade

por Gomez-Roca, Carlos, Cassier, Philippe, Zamarin, Dmitriy, Machiels, Jean-Pascal, Luis Perez Gracia, Jose, Stephen Hodi, F, Taus, Alvaro, Martinez Garcia, Maria, Boni, Valentina, Eder, Joseph P, Hafez, Navid, Sullivan, Ryan, Mcdermott, David, Champiat, Stephane, Aspeslagh, Sandrine, Terret, Catherine, Jegg, Anna-Maria, Jacob, Wolfgang, Cannarile, Michael A, Ries, Carola, Korski, Konstanty, Michielin, Francesca, Christen, Randolph, Babitzki, Galina, Watson, Carl, Meneses-Lorente, Georgina, Weisser, Martin, Rüttinger, Dominik, Delord, Jean-Pierre, Marabelle, Aurelien
Publicado 2022